Geneticure Raises $1M From Xcellerant Ventures

Geneticure, a precision medicine company based in Tucson, AZ, has secured a $1M strategic investment led by Xcellerant Ventures. This funding will support the company's efforts to establish a new clinical laboratory and advance its operations in the life sciences sector.

The investment from Xcellerant Ventures will enable Geneticure to further clinical validation, refine its reimbursement strategy, and prepare for a planned Series A round. Additionally, the funding will help expand the company’s presence in Arizona, which is recognized for its growing life sciences ecosystem.

Geneticure specializes in developing patented genetic tests that aid physicians in predicting how patients will respond to hypertension treatments, including the selection of medication and renal denervation. Utilizing a non-invasive cheek swab test, the company evaluates four physiologic pathways to determine if patients with resistant hypertension will be suitable for renal denervation (RDN), an FDA-approved procedure impacting around 35 million eligible patients in the U.S. These tools are pivotal in guiding treatment decisions and minimizing unnecessary costs to payers.

The focus on identifying suitable candidates for renal denervation is underscored by the notable statistic that over 10 million patients may not benefit from the procedure. As Mike Shufeldt from Xcellerant Ventures remarked, “Renal denervation is a game-changer, but identifying the right candidates has been the critical missing link. Geneticure delivers that clarity.”

Scott Snyder serves as the CEO of Geneticure. The company operates both in Arizona and Minnesota, holding multiple U.S. patents and offering a commercial hypertension test to assist in daily medication selection for patients.

In the context of the funding's strategic importance, Snyder stated, "Increasing our presence in Arizona puts Geneticure close to the clinical partners and talent we need to scale." The infusion of capital not only supports the company’s immediate goals but also positions it for future growth in the healthcare technology landscape.

Company	Geneticure
Round	Strategic investment
Amount	$1M
Lead Investor	Xcellerant Ventures
Investors	Jetstream Venture Fund
Founders	Scott Snyder
Sectors	precision medicine